Alumis (NASDAQ:ALMS) Insider Roy Hardiman Sells 2,692 Shares of Stock

Alumis Inc. (NASDAQ:ALMS) insider Roy Hardiman sold 2,692 shares of the firm’s stock in a transaction dated Monday, August 3rd. The stock was sold at an average price of $26.37, for a total value of $70,988.04. Following the completion of the transaction, the insider owned 207,746 shares of the company’s stock, valued at approximately $5,478,262.02. This represents a 1.28% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Alumis Price Performance

ALMS stock opened at $27.12 on Thursday. The firm has a market capitalization of $3.46 billion, a PE ratio of -13.70 and a beta of -0.69. Alumis Inc. has a twelve month low of $3.76 and a twelve month high of $31.35. The stock has a 50-day simple moving average of $25.37 and a two-hundred day simple moving average of $25.22.

Alumis (NASDAQ:ALMS) last announced its quarterly earnings results on Thursday, May 14th. The company reported ($0.74) earnings per share for the quarter, missing the consensus estimate of ($0.73) by ($0.01). Alumis had a negative net margin of 2,825.70% and a negative return on equity of 88.79%. The company had revenue of $1.74 million for the quarter, compared to the consensus estimate of $2.10 million. On average, equities research analysts anticipate that Alumis Inc. will post -2.87 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

ALMS has been the topic of several research analyst reports. Guggenheim upped their price target on shares of Alumis from $32.00 to $34.00 and gave the stock a “buy” rating in a report on Friday, May 15th. HC Wainwright restated a “neutral” rating and issued a $25.00 target price on shares of Alumis in a research note on Monday. Wells Fargo & Company raised their price target on Alumis from $49.00 to $51.00 and gave the company an “overweight” rating in a report on Friday, May 15th. Citigroup reissued a “buy” rating on shares of Alumis in a report on Tuesday, May 19th. Finally, Wall Street Zen downgraded shares of Alumis from a “hold” rating to a “sell” rating in a research note on Saturday, May 16th. One analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $40.30.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the business. Ieq Capital LLC grew its holdings in shares of Alumis by 4.1% during the 4th quarter. Ieq Capital LLC now owns 17,421 shares of the company’s stock valued at $170,000 after purchasing an additional 690 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its position in Alumis by 26.1% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,724 shares of the company’s stock valued at $46,000 after buying an additional 979 shares during the period. Strs Ohio grew its stake in shares of Alumis by 300.0% during the first quarter. Strs Ohio now owns 2,000 shares of the company’s stock valued at $44,000 after buying an additional 1,500 shares during the last quarter. ProShare Advisors LLC increased its holdings in shares of Alumis by 12.4% in the fourth quarter. ProShare Advisors LLC now owns 14,627 shares of the company’s stock worth $143,000 after buying an additional 1,618 shares during the period. Finally, KBC Group NV bought a new stake in shares of Alumis in the 1st quarter valued at about $42,000.

Key Headlines Impacting Alumis

Here are the key news stories impacting Alumis this week:

• Neutral Sentiment: HC Wainwright reaffirmed its “Neutral” rating on Alumis, indicating the analyst does not currently see a strong enough catalyst to support a more bullish view. HC Wainwright Reaffirms Neutral Rating for Alumis
• Negative Sentiment: Six company insiders, including CFO John R. Schroer, sold a combined 14,953 shares of Alumis on August 3 at an average price of $26.37, generating approximately $394,311 in proceeds. The sales reduced individual holdings by roughly 1.28% to 12.28%; the CFO’s position declined 11.72%. While insider sales can reflect personal financial planning rather than a change in business outlook, the concentration of sales may weigh on investor sentiment. The transactions were reported in SEC filings for Read More., Read More., Read More., Read More., Read More., and Read More..

Alumis Company Profile

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.